1ZP2MA
1ZP2MA, also known as amine or as 1--N-methylpropan-2-amine, is a monoamine releasing agent of the indolizinylethylamine family. It is the analogue and positional isomer of the stimulant-like drug α,N-dimethyltryptamine in which the indole ring has been replaced with an indolizine ring. 1ZP2MA has been found to be a potent dopamine releasing agent, with an of 62nM. It is the α-methyl and N-desmethyl analogue of dimethylamine. 1ZP2MA and 2ZEDMA were patented by Tactogen in 2023.